Abstract
Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have